Pharmacological Inhibition of the SKP2/p300 Signaling Axis Restricts Castration-Resistant Prostate Cancer

Scientists reported that the elevation of SKP2 and EP300 transcriptomic expression is a hallmark of castration-resistant prostate cancer.